Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deramiocel (Primary)
Indications Duchenne muscular dystrophy
Focus Registrational; Therapeutic Use
Acronyms HOPE-3
Sponsors Capricor Therapeutics

Most Recent Events

22 Apr 2026 Results presented in the Capricor Therapeutics Media Release.
22 Apr 2026 According to Capricor Therapeutics media release, the HOPE-3 study results were presented at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Illinois.
12 Mar 2026 According to Capricor Therapeutics media release, the full HOPE-3 study results have been submitted for publication in a peer-reviewed scientific journal.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com